Cornerstone announced the launch of Bethkis (tobramycin inhalation solution) for the management of cystic fibrosis in patients with Pseudomonas aeruginosa.

Bethkis contains 300mg of tobramycin as found in currently available nebulized tobramcyin products (TOBI; Novartis). However, Bethkis’ concentrated formulation delivers the same amount in only 4mLs, allowing efficient nebulization in approximately 15 minutes via the PARI LC PLUS.

Tobramycin, an aminoglycoside antibiotic, becomes concentrated in the airways when inhaled. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventually cell death. Tobramycin has in vitro activity against a wide range of gram-negative organisms including Pseudomonas aeruginosa.

Bethkis is available as  4mL single-use ampules in 56-count cartons.

For more information call (888) 865-1222 or visit